Home LiteratureArticle Details
PMID: 24423116 Published · ppublish English Journal Article Review

Adoptive immunotherapy for cancer or viruses.

Annual review of immunology ·Vol. 32 ·2014-00-00 ·Pages 189-225

Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH

Abstract

Adoptive immunotherapy, or the infusion of lymphocytes, is a promising approach for the treatment of cancer and certain chronic viral infections. The application of the principles of synthetic biology to enhance T cell function has resulted in substantial increases in clinical efficacy. The primary challenge to the field is to identify tumor-specific targets to avoid off-tumor, on-target toxicity. Given recent advances in efficacy in numerous pilot trials, the next steps in clinical development will require multicenter trials to establish adoptive immunotherapy as a mainstream technology.

MeSH Terms
Adoptive Transfer Animals Antigens/genetics,immunology Biomarkers Cell- and Tissue-Based Therapy Gene Transfer Techniques Genetic Therapy Humans Immunotherapy, Adoptive Neoplasms/genetics,immunology,therapy Receptors, Antigen, T-Cell/immunology,metabolism T-Cell Antigen Receptor Specificity/immunology T-Lymphocyte Subsets/cytology,immunology,metabolism Transduction, Genetic Virus Diseases/genetics,immunology,therapy
Chemicals
Antigens Biomarkers Receptors, Antigen, T-Cell
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Maus Marcela V
Translational Research Program, Abramson Cancer Center and.
Fraietta Joseph A
Levine Bruce L
Kalos Michael
Zhao Yangbing
June Carl H
References (199)
199 references, click to expand
  1. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.
    Blood. 2013 Jun 27;121(26):5113-23 PMID: 23610374
  2. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells.
    Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1457-62 PMID: 16432223
  3. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.
    J Immunother. 2010 Nov-Dec;33(9):983-90 PMID: 20948438
  4. T cell assays and MIATA: the essential minimum for maximum impact.
    Immunity. 2012 Jul 27;37(1):1-2 PMID: 22840835
  5. Innovation and opportunity for chimeric antigen receptor targeted T cells.
    Cytotherapy. 2013 Sep;15(9):1046-53 PMID: 23562306
  6. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease.
    N Engl J Med. 2012 Jul 12;367(2):135-45 PMID: 22784116
  7. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.
    J Exp Med. 2005 Oct 3;202(7):907-12 PMID: 16203864
  8. Biomarkers in T cell therapy clinical trials.
    J Transl Med. 2011 Aug 19;9:138 PMID: 21851646
  9. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1.
    J Clin Invest. 2008 Sep;118(9):3132-42 PMID: 18688285
  10. Cytotoxic T lymphocytes for the treatment of viral infections and posttransplant lymphoproliferative disorders in transplant recipients.
    Curr Opin Infect Dis. 2012 Aug;25(4):431-7 PMID: 22614521
  11. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
    Science. 2002 Oct 25;298(5594):850-4 PMID: 12242449
  12. Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells.
    Science. 1997 Apr 11;276(5310):273-6 PMID: 9092480
  13. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells.
    Sci Transl Med. 2012 May 2;4(132):132ra53 PMID: 22553251
  14. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers.
    Nat Methods. 2009 Jul;6(7):520-6 PMID: 19543285
  15. Costimulation light: activation of CD4+ T cells with CD80 or CD86 rather than anti-CD28 leads to a Th2 cytokine profile.
    J Immunol. 2000 Dec 15;165(12):6908-14 PMID: 11120816
  16. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.
    Nat Med. 2006 Apr;12(4):401-9 PMID: 16582916
  17. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects.
    Blood. 2000 Aug 1;96(3):785-93 PMID: 10910888
  18. Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation.
    J Immunol. 2010 Apr 15;184(8):4284-94 PMID: 20220093
  19. Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy.
    Blood. 2009 Oct 22;114(17):3546-56 PMID: 19652199
  20. Sipuleucel-T for the treatment of advanced prostate cancer.
    Semin Oncol. 2012 Jun;39(3):245-52 PMID: 22595047
  21. Retroviral integrations in gene therapy trials.
    Mol Ther. 2012 Apr;20(4):709-16 PMID: 22252453
  22. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
    N Engl J Med. 2011 Aug 25;365(8):725-33 PMID: 21830940
  23. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.
    N Engl J Med. 2009 Feb 12;360(7):692-8 PMID: 19213682
  24. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.
    J Immunother. 2012 Apr;35(3):276-82 PMID: 22421945
  25. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators.
    Nat Biotechnol. 2012 Sep;30(9):858-67 PMID: 22902532
  26. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
    N Engl J Med. 2012 Jun 28;366(26):2455-65 PMID: 22658128
  27. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
    Br J Haematol. 2013 May;161(3):389-401 PMID: 23432359
  28. Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer.
    Blood. 2012 Jun 14;119(24):5688-96 PMID: 22555974
  29. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.
    Nat Med. 2008 Nov;14(11):1264-70 PMID: 18978797
  30. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
    N Engl J Med. 2003 Jan 16;348(3):203-13 PMID: 12529460
  31. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
    J Clin Oncol. 2011 Mar 1;29(7):917-24 PMID: 21282551
  32. Adoptive immunotherapy using human peripheral blood lymphocytes transferred with RNA encoding Her-2/neu-specific chimeric immune receptor in ovarian cancer xenograft model.
    Cancer Gene Ther. 2009 Jun;16(6):489-97 PMID: 19096447
  33. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia.
    Nat Biotechnol. 2013 Jun;31(6):545-52 PMID: 23685480
  34. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia.
    J Exp Med. 2013 Jun 3;210(6):1125-35 PMID: 23712432
  35. Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes.
    Blood. 2010 Dec 2;116(23):5045-9 PMID: 20826724
  36. HIV-1 integration in the human genome favors active genes and local hotspots.
    Cell. 2002 Aug 23;110(4):521-9 PMID: 12202041
  37. Improved survival with ipilimumab in patients with metastatic melanoma.
    N Engl J Med. 2010 Aug 19;363(8):711-23 PMID: 20525992
  38. Superior T memory stem cell persistence supports long-lived T cell memory.
    J Clin Invest. 2013 Feb;123(2):594-9 PMID: 23281401
  39. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.
    Mol Ther. 2010 Feb;18(2):413-20 PMID: 19773745
  40. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.
    Mol Ther. 2011 Mar;19(3):620-6 PMID: 21157437
  41. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.
    Sci Transl Med. 2011 Aug 10;3(95):95ra73 PMID: 21832238
  42. Perspective: assembly line immunotherapy.
    Nature. 2013 Jun 27;498(7455):S17 PMID: 23803946
  43. In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures.
    Blood. 2004 Jul 15;104(2):453-61 PMID: 15031211
  44. Paths to stemness: building the ultimate antitumour T cell.
    Nat Rev Cancer. 2012 Oct;12(10):671-84 PMID: 22996603
  45. Selective modification of antigen-specific T cells by RNA electroporation.
    Hum Gene Ther. 2008 May;19(5):511-21 PMID: 18471037
  46. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.
    Nat Med. 2003 Mar;9(3):279-86 PMID: 12579196
  47. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection.
    Blood. 2011 May 19;117(20):5332-9 PMID: 21403130
  48. Silencing and variegation of gammaretrovirus and lentivirus vectors.
    Hum Gene Ther. 2005 Nov;16(11):1241-6 PMID: 16259557
  49. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy.
    J Immunol. 2004 Dec 15;173(12):7125-30 PMID: 15585832
  50. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease.
    Nat Med. 2010 Feb;16(2):198-204 PMID: 20098431
  51. Distinct TCR signaling pathways drive proliferation and cytokine production in T cells.
    Nat Immunol. 2013 Mar;14(3):262-70 PMID: 23377202
  52. Gene transfer into human T lymphocytes and natural killer cells by Ad5/F35 chimeric adenoviral vectors.
    Exp Hematol. 2004 Jun;32(6):536-46 PMID: 15183894
  53. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.
    Cancer Res. 2007 Apr 15;67(8):3898-903 PMID: 17440104
  54. CARs on track in the clinic.
    Mol Ther. 2011 Mar;19(3):432-8 PMID: 21358705
  55. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.
    Blood. 2011 Nov 3;118(18):4817-28 PMID: 21849486
  56. Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.
    Blood. 2012 Jan 5;119(1):72-82 PMID: 22031866
  57. Treatment of advanced leukemia in mice with mRNA engineered T cells.
    Hum Gene Ther. 2011 Dec;22(12):1575-86 PMID: 21838572
  58. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.
    Nat Biotechnol. 2002 Jan;20(1):70-5 PMID: 11753365
  59. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases.
    Nat Biotechnol. 2008 Jul;26(7):808-16 PMID: 18587387
  60. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.
    Clin Cancer Res. 2009 Feb 15;15(4):1443-51 PMID: 19228745
  61. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
    N Engl J Med. 2012 Jun 28;366(26):2443-54 PMID: 22658127
  62. Mammalian mutagenesis using a highly mobile somatic Sleeping Beauty transposon system.
    Nature. 2005 Jul 14;436(7048):221-6 PMID: 16015321
  63. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
    Cancer Res. 2001 Jun 15;61(12):4766-72 PMID: 11406550
  64. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.
    Biol Blood Marrow Transplant. 2010 Sep;16(9):1245-56 PMID: 20304086
  65. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.
    Proc Natl Acad Sci U S A. 1989 Dec;86(24):10024-8 PMID: 2513569
  66. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.
    Sci Transl Med. 2013 Mar 20;5(177):177ra38 PMID: 23515080
  67. Of mice and not men: differences between mouse and human immunology.
    J Immunol. 2004 Mar 1;172(5):2731-8 PMID: 14978070
  68. Gene therapy targeting hematopoietic cells: better not leave it to chance.
    Acta Haematol. 2003;110(2-3):107-9 PMID: 14583670
  69. A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer.
    Expert Opin Biol Ther. 2009 Dec;9(12):1565-75 PMID: 19916735
  70. Role of the CD28 receptor in T-cell activation.
    Immunol Today. 1990 Jun;11(6):211-6 PMID: 2162180
  71. A brief history of gene therapy.
    Nat Genet. 1992 Oct;2(2):93-8 PMID: 1303270
  72. T cells as a self-referential, sensory organ.
    Annu Rev Immunol. 2007;25:681-95 PMID: 17291190
  73. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.
    N Engl J Med. 2012 Aug 30;367(9):805-16 PMID: 22931314
  74. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.
    Mol Ther. 2010 Apr;18(4):843-51 PMID: 20179677
  75. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.
    J Immunother. 2010 Jan;33(1):1-7 PMID: 19952961
  76. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation.
    Cell Stem Cell. 2013 Jan 3;12(1):114-26 PMID: 23290140
  77. Genetic modification of lymphocytes by retrovirus-based vectors.
    Curr Opin Immunol. 2012 Oct;24(5):598-608 PMID: 22995202
  78. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts.
    N Engl J Med. 1979 May 10;300(19):1068-73 PMID: 34792
  79. Chromosomal transposition of PiggyBac in mouse embryonic stem cells.
    Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9290-5 PMID: 18579772
  80. Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma.
    Mol Ther. 2013 Aug;21(8):1611-20 PMID: 23732988
  81. A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes.
    Clin Immunol. 2002 Dec;105(3):259-72 PMID: 12498807
  82. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.
    Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3360-5 PMID: 19211796
  83. Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5.
    Hum Gene Ther. 2013 Mar;24(3):245-58 PMID: 23360514
  84. Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
    N Engl J Med. 2011 Jun 30;364(26):2507-16 PMID: 21639808
  85. An integrative paradigm to impart quality to correlative science.
    J Transl Med. 2010 Mar 16;8:26 PMID: 20233418
  86. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
    Blood. 2009 Jul 16;114(3):535-46 PMID: 19451549
  87. Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.
    Blood. 2011 Jan 20;117(3):808-14 PMID: 20971955
  88. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients.
    J Clin Invest. 2008 Sep;118(9):3143-50 PMID: 18688286
  89. Engineering lymphocyte subsets: tools, trials and tribulations.
    Nat Rev Immunol. 2009 Oct;9(10):704-16 PMID: 19859065
  90. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow.
    J Exp Med. 1978 Dec 1;148(6):1687-98 PMID: 363972
  91. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.
    Science. 2002 Mar 15;295(5562):2097-100 PMID: 11896281
  92. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes.
    Blood. 2009 Aug 27;114(9):1958-67 PMID: 19443656
  93. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy.
    J Immunother. 2008 Oct;31(8):742-51 PMID: 18779745
  94. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy.
    Science. 2009 Nov 6;326(5954):818-23 PMID: 19892975
  95. Effect of CD3/CD28 bead-activated and expanded T cells on leukemic B cells in chronic lymphocytic leukemia.
    J Immunol. 2005 Jun 1;174(11):6562-3; author reply 6563 PMID: 15905490
  96. Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.
    Cancer Res. 2009 Dec 1;69(23):9003-11 PMID: 19903853
  97. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector.
    Science. 1996 Apr 12;272(5259):263-7 PMID: 8602510
  98. The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex.
    J Immunol. 2010 Jun 15;184(12):6938-49 PMID: 20483753
  99. Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.
    Hematology Am Soc Hematol Educ Program. 2012;2012:143-51 PMID: 23233573
  100. Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability.
    Cancer Res. 2006 Sep 1;66(17):8878-86 PMID: 16951205
  101. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals.
    Nat Med. 2006 Oct;12(10):1160-6 PMID: 16998485
  102. Facilitating matched pairing and expression of TCR chains introduced into human T cells.
    Blood. 2007 Mar 15;109(6):2331-8 PMID: 17082316
  103. Resistance of mature T cells to oncogene transformation.
    Blood. 2008 Sep 15;112(6):2278-86 PMID: 18566328
  104. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.
    Blood. 2006 Feb 15;107(4):1325-31 PMID: 16269610
  105. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain.
    J Immunol. 2004 Jan 1;172(1):104-13 PMID: 14688315
  106. Stable, soluble T-cell receptor molecules for crystallization and therapeutics.
    Protein Eng. 2003 Sep;16(9):707-11 PMID: 14560057
  107. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression.
    Clin Cancer Res. 2011 Oct 1;17(19):6287-97 PMID: 21844012
  108. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy.
    Mol Ther. 2002 Jun;5(6):788-97 PMID: 12027564
  109. CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro.
    Int Immunol. 1995 Jun;7(6):891-904 PMID: 7577797
  110. DCVax-Brain and DC vaccines in the treatment of GBM.
    Expert Opin Investig Drugs. 2009 Apr;18(4):509-19 PMID: 19335279
  111. Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.
    Mol Ther. 2007 May;15(5):981-8 PMID: 17375070
  112. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.
    Blood. 2009 Nov 5;114(19):4283-92 PMID: 19700662
  113. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.
    Blood. 2013 Jun 27;121(26):5154-7 PMID: 23678006
  114. Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells.
    Cell Stem Cell. 2013 Jan 3;12(1):31-6 PMID: 23290135
  115. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning.
    Blood. 2012 May 3;119(18):4133-41 PMID: 22354001
  116. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma.
    Cancer Immunol Immunother. 2013 Jan;62(1):125-35 PMID: 22847020
  117. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.
    J Immunother. 2012 Jul;35(6):460-72 PMID: 22735804
  118. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.
    J Clin Invest. 2008 Jan;118(1):294-305 PMID: 18060041
  119. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.
    Science. 2002 Jun 28;296(5577):2410-3 PMID: 12089448
  120. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.
    Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73 PMID: 12427970
  121. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.
    Blood. 2011 Dec 1;118(23):6050-6 PMID: 21984804
  122. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia.
    Nature. 2010 Sep 16;467(7313):318-22 PMID: 20844535
  123. Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system.
    Blood. 2006 Jan 15;107(2):483-91 PMID: 16189271
  124. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells.
    Nat Biotechnol. 2013 Jan;31(1):71-5 PMID: 23242161
  125. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation.
    Biol Blood Marrow Transplant. 2006 Nov;12(11):1150-60 PMID: 17085308
  126. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection.
    Blood. 2000 Jul 15;96(2):467-74 PMID: 10887107
  127. Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes.
    Mol Med. 2011;17(11-12):1223-32 PMID: 21826372
  128. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
    Clin Cancer Res. 2013 Apr 15;19(8):2048-60 PMID: 23344265
  129. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.
    J Immunother. 2010 Oct;33(8):780-8 PMID: 20842059
  130. CD28/B7 system of T cell costimulation.
    Annu Rev Immunol. 1996;14:233-58 PMID: 8717514
  131. Gene transfer in humans using a conditionally replicating lentiviral vector.
    Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17372-7 PMID: 17090675
  132. Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma.
    Clin Cancer Res. 2013 Jan 1;19(1):106-17 PMID: 23149818
  133. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
    Blood. 2013 Feb 14;121(7):1165-74 PMID: 23243285
  134. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.
    Cancer Res. 2008 Apr 15;68(8):2961-71 PMID: 18413766
  135. Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer.
    Gene Ther. 2009 May;16(5):596-604 PMID: 19158846
  136. Cytokine-independent growth and clonal expansion of a primary human CD8+ T-cell clone following retroviral transduction with the IL-15 gene.
    Blood. 2007 Jun 15;109(12):5168-77 PMID: 17353346
  137. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients.
    Sci Transl Med. 2013 Feb 27;5(174):174ra27 PMID: 23447018
  138. T-cell receptor diversity prevents T-cell lymphoma development.
    Leukemia. 2012 Dec;26(12):2499-507 PMID: 22643706
  139. CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.
    PLoS One. 2013 Apr 09;8(4):e61338 PMID: 23585892
  140. Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein.
    J Immunother. 2010 Sep;33(7):672-83 PMID: 20664359
  141. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy.
    Nat Med. 2010 May;16(5):565-70, 1p following 570 PMID: 20400962
  142. Reconstitution of anti-HIV effector functions of primary human CD8 T lymphocytes by transfer of HIV-specific alphabeta TCR genes.
    Eur J Immunol. 2004 Dec;34(12):3379-88 PMID: 15517606
  143. A human memory T cell subset with stem cell-like properties.
    Nat Med. 2011 Sep 18;17(10):1290-7 PMID: 21926977
  144. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate.
    Clin Cancer Res. 2010 Jan 1;16(1):338-47 PMID: 20048335
  145. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
    Blood. 2012 Mar 22;119(12):2709-20 PMID: 22160384
  146. Effects of CD28 costimulation on long-term proliferation of CD4+ T cells in the absence of exogenous feeder cells.
    J Immunol. 1997 Dec 15;159(12):5921-30 PMID: 9550389
  147. Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis.
    Eur J Immunol. 2009 Feb;39(2):491-506 PMID: 19180469
  148. Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.
    N Engl J Med. 1990 Aug 30;323(9):570-8 PMID: 2381442
  149. T-cell therapy at the threshold.
    Nat Biotechnol. 2012 Jul 10;30(7):611-4 PMID: 22781680
  150. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.
    Clin Cancer Res. 2011 Jul 1;17(13):4550-7 PMID: 21498393
  151. Sleeping beauty system to redirect T-cell specificity for human applications.
    J Immunother. 2013 Feb;36(2):112-23 PMID: 23377665
  152. Prospects for human gene therapy.
    Science. 1984 Oct 26;226(4673):401-9 PMID: 6093246
  153. Inducible apoptosis as a safety switch for adoptive cell therapy.
    N Engl J Med. 2011 Nov 3;365(18):1673-83 PMID: 22047558
  154. Nivolumab plus ipilimumab in advanced melanoma.
    N Engl J Med. 2013 Jul 11;369(2):122-33 PMID: 23724867
  155. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation.
    Mol Ther. 2006 Jan;13(1):151-9 PMID: 16140584
  156. High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow.
    Blood. 2009 Mar 5;113(10):2238-44 PMID: 18997173
  157. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy.
    Blood. 2005 Jan 1;105(1):241-50 PMID: 15345595
  158. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor.
    N Engl J Med. 1995 Oct 19;333(16):1038-44 PMID: 7675046
  159. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.
    Mol Ther. 2007 Apr;15(4):825-33 PMID: 17299405
  160. CARs in chronic lymphocytic leukemia -- ready to drive.
    Curr Hematol Malig Rep. 2013 Mar;8(1):60-70 PMID: 23225251
  161. High efficiency gene transfer into murine T cell clones using a retroviral vector.
    J Immunol. 1986 Mar 1;136(5):1876-9 PMID: 3005404
  162. How do CARs work?: Early insights from recent clinical studies targeting CD19.
    Oncoimmunology. 2012 Dec 1;1(9):1577-1583 PMID: 23264903
  163. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors.
    Blood. 2013 Aug 22;122(8):1341-9 PMID: 23741009
  164. Stem cell-like plasticity of naïve and distinct memory CD8+ T cell subsets.
    Semin Immunol. 2009 Apr;21(2):62-8 PMID: 19269852
  165. Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity.
    J Immunol. 2001 Dec 1;167(11):6356-65 PMID: 11714800
  166. Analysis of lentiviral vector integration in HIV+ study subjects receiving autologous infusions of gene modified CD4+ T cells.
    Mol Ther. 2009 May;17(5):844-50 PMID: 19259065
  167. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.
    J Immunother. 2013 Feb;36(2):133-51 PMID: 23377668
  168. Cancer regression in patients after transfer of genetically engineered lymphocytes.
    Science. 2006 Oct 6;314(5796):126-9 PMID: 16946036
  169. Interleukin-2 and regulatory T cells in graft-versus-host disease.
    N Engl J Med. 2011 Dec 1;365(22):2055-66 PMID: 22129252
  170. Intrinsic resistance to T cell infection with HIV type 1 induced by CD28 costimulation.
    J Immunol. 1997 Jun 1;158(11):5545-53 PMID: 9164979
  171. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.
    Blood. 2007 Aug 15;110(4):1123-31 PMID: 17468341
  172. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.
    J Immunol. 2005 Nov 1;175(9):6169-76 PMID: 16237114
  173. T cells from patients with Hodgkin's disease have a defective T-cell receptor zeta chain expression that is reversible by T-cell stimulation with CD3 and CD28.
    Blood. 1996 Jul 1;88(1):236-41 PMID: 8704179
  174. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.
    Blood. 2013 Aug 8;122(6):863-71 PMID: 23770775
  175. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.
    J Clin Oncol. 2006 May 1;24(13):e20-2 PMID: 16648493
  176. BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer.
    Oncoimmunology. 2012 Dec 1;1(9):1476-1483 PMID: 23264894
  177. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.
    Proc Natl Acad Sci U S A. 2009 Oct 13;106(41):17469-74 PMID: 19805141
  178. Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction.
    J Gene Med. 2010 Mar;12(3):255-65 PMID: 20186995
  179. Immunotherapy of cancer in 2012.
    CA Cancer J Clin. 2012 Sep-Oct;62(5):309-35 PMID: 22576456
  180. In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia.
    J Immunol. 2005 Feb 15;174(4):2366-75 PMID: 15699173
  181. Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes.
    Hum Gene Ther. 2009 Jan;20(1):51-61 PMID: 19025415
  182. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.
    Cancer Immunol Res. 2013 Jul;1:26-31 PMID: 24432303
  183. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.
    Nat Immunol. 2001 Oct;2(10):962-70 PMID: 11577350
  184. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
    Cancer Res. 2010 Nov 15;70(22):9053-61 PMID: 20926399
  185. Cell-intrinsic and vector-related properties cooperate to determine the incidence and consequences of insertional mutagenesis.
    Mol Ther. 2009 Sep;17(9):1537-47 PMID: 19532134
  186. Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells.
    Blood. 2011 Jan 6;117(1):72-82 PMID: 20889925
  187. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.
    N Engl J Med. 2013 Apr 18;368(16):1509-1518 PMID: 23527958
  188. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB.
    Nat Biotechnol. 2002 Feb;20(2):143-8 PMID: 11821859
  189. Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression.
    Immunol Res. 2006;34(1):67-87 PMID: 16720899
  190. T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years.
    Science. 1995 Oct 20;270(5235):475-80 PMID: 7570001
  191. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA- immunodeficient patients.
    Science. 1995 Oct 20;270(5235):470-5 PMID: 7570000
  192. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells.
    Nat Med. 2006 Dec;12(12):1397-402 PMID: 17115047
  193. Human TCR that incorporate CD3zeta induce highly preferred pairing between TCRalpha and beta chains following gene transfer.
    J Immunol. 2008 Jun 1;180(11):7736-46 PMID: 18490778
  194. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation.
    Science. 1996 Jun 28;272(5270):1939-43 PMID: 8658167
  195. High-throughput microfluidic single-cell RT-qPCR.
    Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):13999-4004 PMID: 21808033
  196. Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells.
    J Immunol. 2007 Nov 1;179(9):5803-10 PMID: 17947653
  197. Ultra-sensitive detection of rare T cell clones.
    J Immunol Methods. 2012 Jan 31;375(1-2):14-9 PMID: 21945395
  198. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.
    N Engl J Med. 2008 Jun 19;358(25):2698-703 PMID: 18565862
  199. Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells.
    J Immunol. 2008 Jan 1;180(1):391-401 PMID: 18097040
Article Info
Journal
Annual review of immunology
Abbr.
Annu Rev Immunol
ISSN
1545-3278
DOI
10.1146/annurev-immunol-032713-120136
Published
2014-00-00
Epub
2014-00-09
Pages
189-225
Language
English
Region
United States
NLM ID
8309206
PMCID
PMC4533835
Subset
IM
Grants
NCI NIH HHS · K08 CA166039 · United States
NCI NIH HHS · R01 CA120409 · United States
External Links
PubMed source DOI: 10.1146/annurev-immunol-032713-120136 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2